How to interpret and use COVID-19 serology and immunology tests

Although molecular tests are considered the reference standard for coronavirus disease 2019 (COVID-19) diagnostics, serological and immunological tests may be useful in specific settings. This review summarizes the underlying principles and performance of COVID-19 serological and immunological testi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical microbiology and infection 2021-07, Vol.27 (7), p.981-986
Hauptverfasser: Ong, David S.Y., Fragkou, Paraskevi C., Schweitzer, Valentijn A., Chemaly, Roy F., Moschopoulos, Charalampos D., Skevaki, Chrysanthi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 986
container_issue 7
container_start_page 981
container_title Clinical microbiology and infection
container_volume 27
creator Ong, David S.Y.
Fragkou, Paraskevi C.
Schweitzer, Valentijn A.
Chemaly, Roy F.
Moschopoulos, Charalampos D.
Skevaki, Chrysanthi
description Although molecular tests are considered the reference standard for coronavirus disease 2019 (COVID-19) diagnostics, serological and immunological tests may be useful in specific settings. This review summarizes the underlying principles and performance of COVID-19 serological and immunological testing. Selected peer-reviewed publications on COVID-19 related serology and immunology published between December 2019 and March 2021. Serological tests are highly specific but heterogeneous in their sensitivity for the diagnosis of COVID-19. For certain indications, including delayed disease presentations, serological tests can have added value. The presence of antibodies against SARS-CoV-2 may indicate a recent or past COVID-19 infection. Lateral flow immunoassay (LFIA) antibody tests have the advantages of being easy and fast to perform, but many have a low sensitivity in acute settings. Enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassays (CLIAs) have higher sensitivities. Besides humoral immunity, cellular immunity is also essential for successful host defences against viruses. Enzyme-linked immunospot (ELISpot) assays can be used to measure T-cell responses against SARS-CoV-2. The presence of cross-reactive SARS-CoV-2-specific T cells in never exposed patients suggests the possibility of cellular immunity induced by other circulating coronaviruses. T-cell responses against SARS-CoV-2 have also been detected in recovered COVID-19 patients with no detectable antibodies. Serological and immunological tests are primarily applied for population-based seroprevalence studies to evaluate the effectiveness of COVID-19 control measures and increase our understanding of the immunology behind COVID-19. Combining molecular diagnostics with serological tests may optimize the detection of COVID-19. As not all infected patients will develop antibodies against SARS-CoV-2, assessment of cellular immunity may provide complementary information on whether a patient has been previously infected with COVID-19. More studies are needed to understand the correlations of these serological and immunological parameters with protective immunity, taking into account the different circulating virus variants.
doi_str_mv 10.1016/j.cmi.2021.05.001
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8106522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X21002214</els_id><sourcerecordid>2526147205</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-f001166b51343b868db0291aba8be113a836797379348510d91472d054ff0ead3</originalsourceid><addsrcrecordid>eNp9kEFP3DAQhS3UqlDoD-BS5dhL0hk7dmIhUVVbWpCQuEDVm-UkE-pVEm_thIp_j5elCC49jUfz5s3zx9gxQoGA6vO6aEdXcOBYgCwAcI8dYKl0Dkrjm_RGXedVKX7ts_cxrgGAC1G-Y_tC6EoCyAP25dz_zWafuWmmsAk0Z3bqsiVStrr6efEtR51FCn7wt_ePEzeOy7RrZ4pzPGJveztE-vBUD9nN97Pr1Xl-efXjYvX1Mm9LiXPep3CoVCNRlKKpVd01wDXaxtYNIQpbC1XpSlRalLVE6DSWFe9Aln0PZDtxyE53vpulGalraZqDHcwmuNGGe-OtM68nk_ttbv2dqRGU5DwZfHoyCP7PkqKb0cWWhsFO5JdouORqexNkkuJO2gYfY6D--QyC2YI3a5PAmy14A9Kkv6Wdjy_zPW_8I50EJzsBJUp3joKJraOppc4FamfTefcf-wfUyJIr</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2526147205</pqid></control><display><type>article</type><title>How to interpret and use COVID-19 serology and immunology tests</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Ong, David S.Y. ; Fragkou, Paraskevi C. ; Schweitzer, Valentijn A. ; Chemaly, Roy F. ; Moschopoulos, Charalampos D. ; Skevaki, Chrysanthi</creator><creatorcontrib>Ong, David S.Y. ; Fragkou, Paraskevi C. ; Schweitzer, Valentijn A. ; Chemaly, Roy F. ; Moschopoulos, Charalampos D. ; Skevaki, Chrysanthi ; the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV) ; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)</creatorcontrib><description>Although molecular tests are considered the reference standard for coronavirus disease 2019 (COVID-19) diagnostics, serological and immunological tests may be useful in specific settings. This review summarizes the underlying principles and performance of COVID-19 serological and immunological testing. Selected peer-reviewed publications on COVID-19 related serology and immunology published between December 2019 and March 2021. Serological tests are highly specific but heterogeneous in their sensitivity for the diagnosis of COVID-19. For certain indications, including delayed disease presentations, serological tests can have added value. The presence of antibodies against SARS-CoV-2 may indicate a recent or past COVID-19 infection. Lateral flow immunoassay (LFIA) antibody tests have the advantages of being easy and fast to perform, but many have a low sensitivity in acute settings. Enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassays (CLIAs) have higher sensitivities. Besides humoral immunity, cellular immunity is also essential for successful host defences against viruses. Enzyme-linked immunospot (ELISpot) assays can be used to measure T-cell responses against SARS-CoV-2. The presence of cross-reactive SARS-CoV-2-specific T cells in never exposed patients suggests the possibility of cellular immunity induced by other circulating coronaviruses. T-cell responses against SARS-CoV-2 have also been detected in recovered COVID-19 patients with no detectable antibodies. Serological and immunological tests are primarily applied for population-based seroprevalence studies to evaluate the effectiveness of COVID-19 control measures and increase our understanding of the immunology behind COVID-19. Combining molecular diagnostics with serological tests may optimize the detection of COVID-19. As not all infected patients will develop antibodies against SARS-CoV-2, assessment of cellular immunity may provide complementary information on whether a patient has been previously infected with COVID-19. More studies are needed to understand the correlations of these serological and immunological parameters with protective immunity, taking into account the different circulating virus variants.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1016/j.cmi.2021.05.001</identifier><identifier>PMID: 33975005</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antibodies ; Antibodies, Viral - blood ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - immunology ; COVID-19 Serological Testing ; Humans ; Immunity ; Immunity, Cellular ; Immunity, Humoral ; Immunoassay ; Narrative Review ; SARS-CoV-2 ; SARS-CoV-2 - immunology ; SARS-CoV-2 - isolation &amp; purification ; Sensitivity and Specificity ; Serology ; T cell</subject><ispartof>Clinical microbiology and infection, 2021-07, Vol.27 (7), p.981-986</ispartof><rights>2021 European Society of Clinical Microbiology and Infectious Diseases</rights><rights>Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><rights>2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2021 European Society of Clinical Microbiology and Infectious Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-f001166b51343b868db0291aba8be113a836797379348510d91472d054ff0ead3</citedby><cites>FETCH-LOGICAL-c451t-f001166b51343b868db0291aba8be113a836797379348510d91472d054ff0ead3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33975005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ong, David S.Y.</creatorcontrib><creatorcontrib>Fragkou, Paraskevi C.</creatorcontrib><creatorcontrib>Schweitzer, Valentijn A.</creatorcontrib><creatorcontrib>Chemaly, Roy F.</creatorcontrib><creatorcontrib>Moschopoulos, Charalampos D.</creatorcontrib><creatorcontrib>Skevaki, Chrysanthi</creatorcontrib><creatorcontrib>the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)</creatorcontrib><creatorcontrib>European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)</creatorcontrib><title>How to interpret and use COVID-19 serology and immunology tests</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>Although molecular tests are considered the reference standard for coronavirus disease 2019 (COVID-19) diagnostics, serological and immunological tests may be useful in specific settings. This review summarizes the underlying principles and performance of COVID-19 serological and immunological testing. Selected peer-reviewed publications on COVID-19 related serology and immunology published between December 2019 and March 2021. Serological tests are highly specific but heterogeneous in their sensitivity for the diagnosis of COVID-19. For certain indications, including delayed disease presentations, serological tests can have added value. The presence of antibodies against SARS-CoV-2 may indicate a recent or past COVID-19 infection. Lateral flow immunoassay (LFIA) antibody tests have the advantages of being easy and fast to perform, but many have a low sensitivity in acute settings. Enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassays (CLIAs) have higher sensitivities. Besides humoral immunity, cellular immunity is also essential for successful host defences against viruses. Enzyme-linked immunospot (ELISpot) assays can be used to measure T-cell responses against SARS-CoV-2. The presence of cross-reactive SARS-CoV-2-specific T cells in never exposed patients suggests the possibility of cellular immunity induced by other circulating coronaviruses. T-cell responses against SARS-CoV-2 have also been detected in recovered COVID-19 patients with no detectable antibodies. Serological and immunological tests are primarily applied for population-based seroprevalence studies to evaluate the effectiveness of COVID-19 control measures and increase our understanding of the immunology behind COVID-19. Combining molecular diagnostics with serological tests may optimize the detection of COVID-19. As not all infected patients will develop antibodies against SARS-CoV-2, assessment of cellular immunity may provide complementary information on whether a patient has been previously infected with COVID-19. More studies are needed to understand the correlations of these serological and immunological parameters with protective immunity, taking into account the different circulating virus variants.</description><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 Serological Testing</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunity, Cellular</subject><subject>Immunity, Humoral</subject><subject>Immunoassay</subject><subject>Narrative Review</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS-CoV-2 - isolation &amp; purification</subject><subject>Sensitivity and Specificity</subject><subject>Serology</subject><subject>T cell</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFP3DAQhS3UqlDoD-BS5dhL0hk7dmIhUVVbWpCQuEDVm-UkE-pVEm_thIp_j5elCC49jUfz5s3zx9gxQoGA6vO6aEdXcOBYgCwAcI8dYKl0Dkrjm_RGXedVKX7ts_cxrgGAC1G-Y_tC6EoCyAP25dz_zWafuWmmsAk0Z3bqsiVStrr6efEtR51FCn7wt_ePEzeOy7RrZ4pzPGJveztE-vBUD9nN97Pr1Xl-efXjYvX1Mm9LiXPep3CoVCNRlKKpVd01wDXaxtYNIQpbC1XpSlRalLVE6DSWFe9Aln0PZDtxyE53vpulGalraZqDHcwmuNGGe-OtM68nk_ttbv2dqRGU5DwZfHoyCP7PkqKb0cWWhsFO5JdouORqexNkkuJO2gYfY6D--QyC2YI3a5PAmy14A9Kkv6Wdjy_zPW_8I50EJzsBJUp3joKJraOppc4FamfTefcf-wfUyJIr</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Ong, David S.Y.</creator><creator>Fragkou, Paraskevi C.</creator><creator>Schweitzer, Valentijn A.</creator><creator>Chemaly, Roy F.</creator><creator>Moschopoulos, Charalampos D.</creator><creator>Skevaki, Chrysanthi</creator><general>Elsevier Ltd</general><general>European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210701</creationdate><title>How to interpret and use COVID-19 serology and immunology tests</title><author>Ong, David S.Y. ; Fragkou, Paraskevi C. ; Schweitzer, Valentijn A. ; Chemaly, Roy F. ; Moschopoulos, Charalampos D. ; Skevaki, Chrysanthi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-f001166b51343b868db0291aba8be113a836797379348510d91472d054ff0ead3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 Serological Testing</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunity, Cellular</topic><topic>Immunity, Humoral</topic><topic>Immunoassay</topic><topic>Narrative Review</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS-CoV-2 - isolation &amp; purification</topic><topic>Sensitivity and Specificity</topic><topic>Serology</topic><topic>T cell</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ong, David S.Y.</creatorcontrib><creatorcontrib>Fragkou, Paraskevi C.</creatorcontrib><creatorcontrib>Schweitzer, Valentijn A.</creatorcontrib><creatorcontrib>Chemaly, Roy F.</creatorcontrib><creatorcontrib>Moschopoulos, Charalampos D.</creatorcontrib><creatorcontrib>Skevaki, Chrysanthi</creatorcontrib><creatorcontrib>the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)</creatorcontrib><creatorcontrib>European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ong, David S.Y.</au><au>Fragkou, Paraskevi C.</au><au>Schweitzer, Valentijn A.</au><au>Chemaly, Roy F.</au><au>Moschopoulos, Charalampos D.</au><au>Skevaki, Chrysanthi</au><aucorp>the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)</aucorp><aucorp>European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How to interpret and use COVID-19 serology and immunology tests</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>27</volume><issue>7</issue><spage>981</spage><epage>986</epage><pages>981-986</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>Although molecular tests are considered the reference standard for coronavirus disease 2019 (COVID-19) diagnostics, serological and immunological tests may be useful in specific settings. This review summarizes the underlying principles and performance of COVID-19 serological and immunological testing. Selected peer-reviewed publications on COVID-19 related serology and immunology published between December 2019 and March 2021. Serological tests are highly specific but heterogeneous in their sensitivity for the diagnosis of COVID-19. For certain indications, including delayed disease presentations, serological tests can have added value. The presence of antibodies against SARS-CoV-2 may indicate a recent or past COVID-19 infection. Lateral flow immunoassay (LFIA) antibody tests have the advantages of being easy and fast to perform, but many have a low sensitivity in acute settings. Enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassays (CLIAs) have higher sensitivities. Besides humoral immunity, cellular immunity is also essential for successful host defences against viruses. Enzyme-linked immunospot (ELISpot) assays can be used to measure T-cell responses against SARS-CoV-2. The presence of cross-reactive SARS-CoV-2-specific T cells in never exposed patients suggests the possibility of cellular immunity induced by other circulating coronaviruses. T-cell responses against SARS-CoV-2 have also been detected in recovered COVID-19 patients with no detectable antibodies. Serological and immunological tests are primarily applied for population-based seroprevalence studies to evaluate the effectiveness of COVID-19 control measures and increase our understanding of the immunology behind COVID-19. Combining molecular diagnostics with serological tests may optimize the detection of COVID-19. As not all infected patients will develop antibodies against SARS-CoV-2, assessment of cellular immunity may provide complementary information on whether a patient has been previously infected with COVID-19. More studies are needed to understand the correlations of these serological and immunological parameters with protective immunity, taking into account the different circulating virus variants.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33975005</pmid><doi>10.1016/j.cmi.2021.05.001</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1198-743X
ispartof Clinical microbiology and infection, 2021-07, Vol.27 (7), p.981-986
issn 1198-743X
1469-0691
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8106522
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Antibodies
Antibodies, Viral - blood
COVID-19
COVID-19 - diagnosis
COVID-19 - immunology
COVID-19 Serological Testing
Humans
Immunity
Immunity, Cellular
Immunity, Humoral
Immunoassay
Narrative Review
SARS-CoV-2
SARS-CoV-2 - immunology
SARS-CoV-2 - isolation & purification
Sensitivity and Specificity
Serology
T cell
title How to interpret and use COVID-19 serology and immunology tests
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A31%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20to%20interpret%20and%20use%20COVID-19%20serology%20and%20immunology%20tests&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Ong,%20David%20S.Y.&rft.aucorp=the%20European%20Society%20of%20Clinical%20Microbiology%20and%20Infectious%20Diseases%20(ESCMID)%20Study%20Group%20for%20Respiratory%20Viruses%20(ESGREV)&rft.date=2021-07-01&rft.volume=27&rft.issue=7&rft.spage=981&rft.epage=986&rft.pages=981-986&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1016/j.cmi.2021.05.001&rft_dat=%3Cproquest_pubme%3E2526147205%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2526147205&rft_id=info:pmid/33975005&rft_els_id=S1198743X21002214&rfr_iscdi=true